Akebia GAAP EPS of -$0.05 misses by $0.01, revenue of $57.6M beats by $11.51M
Source: SeekingAlpha
2026-02-26 07:07:57 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
- Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
- Akebia Q4 2025 Earnings Preview
- Quant snapshot: Amerigo, Allianz lead strong buys as Ashford Hospitality, Hudson Pacific lag
- Seeking Alpha’s Quant Rating on Akebia
Read the full article on Seeking Alpha
For further details see:
Akebia GAAP EPS of -$0.05 misses by $0.01, revenue of $57.6M beats by $11.51M
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
2.89% G/L:
$1.425 Last:
2,079,511 Volume:
$1.41 Open:
AKBA Latest News
March 03, 2026 08:00:00 am
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 07:00:00 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
